2상모집 중

GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5

연구 개요

A Phase 2 Study to Evaluate Safety and Efficacy of Teclistamab-, Talquetamab-, and JNJ-79635322-based Combination Regimens in Participants with Newly Diagnosed Transplant Eligible Multiple Myeloma OBJECTIVES: To evaluate the safety and tolerability of teclistamab-, talquetamab-, and JNJ-79635322-based combination regimens over the entire treatment phase for each arm, in participants with ND-TEMM To evaluate the efficacy of teclistamab- and talquetamab-based combination regimens as induction and post-transplant maintenance treatments; JNJ-79635322-based combinations as induction and as replacement for HDT+ASCT following induction; and teclistamab in combination with talquetamab

스폰서
협력: 얀센(J&J)
적응증
Multiple Myeloma
중재
Teclistamab (Tec), Daratumumab, Dexamethasone, Lenalidomide, Bortezomib, Talquetamab, JNJ-79635322
목표 등록
160
시작일
2022-12-01
완료(예정)
2029-09-15

BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.